IMRX
NASDAQ · Biotechnology
Immuneering Corp - Class A
$4.51
+0.05 (+1.12%)
Open$4.53
Previous Close$4.46
Day High$4.57
Day Low$4.43
52W High$10.08
52W Low$2.90
Volume—
Avg Volume590.2K
Market Cap291.78M
P/E Ratio—
EPS$-1.17
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
-21.5% upside
Current
$4.51
$4.51
Target
$3.54
$3.54
$2.50
$3.54 avg
$3.55
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 183.49M | 183.65M | 175.87M |
| Net Income | 12.93M | 12.84M | 10.17M |
| Profit Margin | 7.1% | 7.0% | 5.8% |
| EBITDA | 22.71M | 20.96M | 19.85M |
| Free Cash Flow | 10.88M | 9.00M | 9.93M |
| Rev Growth | -6.7% | +18.5% | +10.5% |
| Debt/Equity | 0.36 | 0.44 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |